"Electromagnetical Stimulation of Phrenic Nerve to Generate Contraction of the Diaphragm"

January 5, 2022 updated by: Stimit AG

"Electromagnetical Stimulation of the Phrenic Nerve to Generate Contraction of the Diaphragm in Healthy Subjects and Anaesthetized and Intubated Patients - a Feasibility Study"

The scientific study is intended to show that external non-invasive electromagnetic stimulation can be used to safely and effectively stimulate the phrenic nerve in awake healthy subjects as well as in ventilated, anesthetized patients and that the stimulation can generate a diaphragmatic contraction that generates significant breath volume - a Controlled Own Breath (COB).

Also of interest is the reproducibility of the generated diaphragmatic movements and the reliability of different feedback signals for detecting the generated diaphragmatic contraction. This applies to inspiration and expiration detection for subsequent synchronization mechanisms of the magnetic stimulator for patient-initiated breathing as well as to contraction intensity. Further, the characterization of the position finding process is of great importance, so that technical developments can further simplify the process of coil positioning in the future. The possible occurrence of discomfort and pain sensation will also be investigated in awake healthy volunteers. Different stimulation protocols will be used.

Finally, it will be investigated whether an adjusted coil position still triggers reproducible diaphragmatic contractions after removal and repositioning in the same configuration. The knowledge gained will be used to further develop the technique and to prepare a study in critically ill, ventilated patients where the diaphragmatic muscle is to be treated preventively by stimulating the phrenic nerve, in order to prevent atrophy of the muscle.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nottwil, Switzerland
        • Swiss Paraplegic Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Persons aged > 18 years
  • Applicable for Group 2: planned for elective surgery
  • No relevant pre-existing conditions - corresponding to American Society of Anesthesiologists (ASA) level of I-II.
  • Written informed consent by the patient for participation in the study given

Exclusion Criteria:

  • chronic lung diseases (bronchial asthma, COPD)
  • known diaphragmatic weakness
  • known neurological conditions with motor muscle weakness
  • known paralysis of the phrenic nerve
  • conditions that limit the mobility of the diaphragm (high intra-abdominal pressure, ascites, BMI >30)
  • not able to read and understand the national language German
  • skin lesions, infections or strictures in the neck area
  • persons with Implanted cardiac support systems (pacemaker, implanted defibrillator)
  • persons with implanted medical pumps
  • pregnant women
  • persons deprived of liberty by administrative or judicial decision or under legal guardianship.
  • Participation in another clinical trial
  • Applicable for group 2 (intubated and mechanically ventilated) patients: Exclusion criteria at the time of stimulation:

    • Unstable patient after induction of anesthesia and intubation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Phrenic nerve stimulation with Stimit Activator

The Stimit Activator Device is composed of three components.

  1. A magnetic stimulator generating current pulses
  2. A novel Stimit coil design optimized for phrenic nerve stimulation
  3. A coil positioning device for quick, easy and reproducible coil positioning

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in airway pressure / endpoint Group 1:
Time Frame: During stimulation
The primary outcome / endpoint is the change in airway pressure at the mouth during stimulation as seen with or without the use of the ventilator
During stimulation
Discomfort / pain during stimulation measured by Visual Analogue Scale / endpoint Group 1:
Time Frame: During stimulation
The primary outcome / endpoint is the level of discomfort / pain during stimulation, measured by Visual Analogue Scale(0-100, with 100 being worst pain / discomfort)
During stimulation
Change in airway pressure / endpoint Group 2:
Time Frame: During stimulation
The primary outcome / endpoint is the change in airway pressure during stimulation as seen with or without the use of the ventilator during stimulation.
During stimulation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diaphragmatic contraction
Time Frame: During stimulation
Diaphragmatic contraction at 20 percent / 30 percent / 40 percent stimulation intensity at the optimal stimulation site, at 25 Hz and 2s stimulation time
During stimulation
Feedback signals
Time Frame: During stimulation
Change of the maximum value of the feedback signals in percent of the maximum depending on the coil position (in 0.5 cm steps; at least 3 steps in each direction)
During stimulation
Time stimulation start to end
Time Frame: During stimulation

Time (mean value & standard deviation) between stimulation start and stimulation end (trigger signal start and end) until the feedback signals from:

  • the abdominal belt,
  • the Diaphragm Thickening Fraction ((TFdi) according to standard procedure, measured via ultrasound during stimulation), and
  • the Diaphragm Excursion Signal "respons" (measured by ultrasound during stimulation)
During stimulation
Correlation stimulation intensity and diaphragm contraction
Time Frame: During stimulation
Correlation between stimulation intensity (power output in percent) and diaphragm contraction, measured by tidal volume, at the optimal coil position at given frequency (25 Hz) and given stimulation duration
During stimulation
Optimal stimulation site - distance
Time Frame: During stimulation
Distance from anatomical landmark (a) to optimal stimulation site (b) and phrenic nerve (c) using ultrasound and between b and c
During stimulation
Optimal stimulation site - time
Time Frame: During stimulation
Time from the start of coil positioning to finding a coil positioning which produces the maximum diaphragmatic contraction at a given stimulation intensity and frequency of 25 Hz
During stimulation
Tidal volumes
Time Frame: During stimulation
The mean and standard deviation of generated tidal volumes for ten stimulations performed without the subject being ventilated
During stimulation
Skin reactions / musle activation
Time Frame: During stimulation
For Group 1: evaluation of stimulation-induced local skin reactions or muscle activation leading to paresthesia in the dental area
During stimulation
Safety outcome
Time Frame: During stimulation and postoperatively, usually within 2-3 hours

The safety outcome/ endpoint is the occurrence of the following events during stimulation:

  • Device related Adverse Events
  • Device related Serious Adverse Events
During stimulation and postoperatively, usually within 2-3 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Michael Baumberger, MD, Swiss Paraplegic Center Nottwil

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 25, 2021

Primary Completion (ACTUAL)

December 13, 2021

Study Completion (ACTUAL)

December 13, 2021

Study Registration Dates

First Submitted

April 30, 2021

First Submitted That Met QC Criteria

May 10, 2021

First Posted (ACTUAL)

May 13, 2021

Study Record Updates

Last Update Posted (ACTUAL)

January 6, 2022

Last Update Submitted That Met QC Criteria

January 5, 2022

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • Stimit swiss I

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Subjects

Clinical Trials on Stimit Activator

3
Subscribe